[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578224":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":41,"centralContacts":46,"locations":55,"responsibleParty":70,"collaborators":40,"id":72,"slug":40,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":40,"enrollmentInfo":82,"targetDuration":40,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":58,"whyStopped":40,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Oxy part A: 7 Day treatment","EXPERIMENTAL","Syntocinon, 24 IU, administered over a 7 day period",[13],"Drug: Oxytocin nasal spray",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo part A: 7 Day treatment","PLACEBO_COMPARATOR","0.9% sodium chloride, administered over a 7 day period",[19],"Drug: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Oxy part B: single application","Syntocinon, 24 IU, administered once",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Placebo Oxy part B: single application","0.9% sodium chloride, administered once",[19],[29,36],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","Oxytocin nasal spray","24 IU",[9,21],[35],"Syntocinon",{"type":30,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Placebo","0.9% NaCl",[25,15],null,[42],{"name":43,"affiliation":44,"role":45},"Mirjam Christ-Crain, Prof. MD","Universitätsspital Basel","PRINCIPAL_INVESTIGATOR",[47,51],{"name":43,"role":48,"phone":49,"phoneExt":40,"email":50},"CONTACT","+41 61 328 70 80","mirjam.christ-crain@usb.ch",{"name":52,"role":48,"phone":53,"phoneExt":40,"email":54},"Cemile Bathelt","+41 61 556 54 07","cemile.bathelt@usb.ch",[56],{"facility":57,"status":58,"city":59,"state":40,"zip":60,"country":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"University Hospital Basel","RECRUITING","Basel","4031","Switzerland",{"type":63,"coordinates":64},"Point",[65,66],7.57327,47.55839,{"lat":66,"lon":65},[69],{"name":52,"role":48,"phone":53,"phoneExt":40,"email":54},{"type":71,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100578224",false,"NCT06808516","Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls","The OxyPLEASURE Study - Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency (Central Diabetes Insipidus) and Healthy Controls - a Double-blind Randomized Placebo-controlled Crossover Trial","OxyPLEASURE","Inclusion Criteria for healthy controls:\n\n* Adult healthy volunteers aged 18 years and above\n* Matched for age, sex, BMI, and menopause\u002Fhormonal contraceptives to patients\n* No medication, except hormonal contraception\n* At least mild impairment in sexual function and satisfaction, defined as an ASEX-score ≥10 points and an NSSS-S score ≤ 48 points\n* Only Part A: Participants must be sexually active (at least once a week sexual intercourse) and in a current partnership for at least 6 months\n\nInclusion criteria for patients:\n\n* Adult patients aged 18 years and above, with a confirmed diagnosis of AVP deficiency based on established criteria\n* Stable hormone replacement therapy for at least three months with desmopressin and, in case of additional anterior pituitary deficiencies, with the respective substitution therapies\n* At least mild impairment in sexual function and satisfaction, defined as an ASEX-score ≥10 points and an NSSS-S score ≤ 48 points\n* Only Part A: Participants must be sexually active (at least once a week sexual intercourse) and in a current partnership for at least 6 months\n\nExclusion Criteria:\n\n* Pregnancy and breastfeeding within the last eight weeks\n* Participation in a trial with investigational drugs within 30 days\n* Active substance use disorder within the last six months\n* Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n* Current or previous psychotic disorder (e.g., schizophrenia)",true,"ALL","18 Years",{"count":83,"type":84},42,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and empathy in a clinical setting and is designed for single participants and those in partnerships.",[90,91,92],"Arginine Vasopressin Deficiency","Central Diabetes Insipidus","Oxytocin Deficiency",[94,95],"Nasal oxytocin","Sexual Well-Being","2025-09-29",{"date":98,"type":99},"2025-10-03","ACTUAL",{"date":101,"type":99},"2025-07-01",{"date":103,"type":84},"2026-12",{"name":5,"class":6},1]